Richard R. Kerr
Urology Nevada survivor: ‘Why waste time on anger?’
Urologist Christine N. Lajeunesse, MD, who survived the shooting at Urology Nevada 7 months ago, tells a local TV station that her recovery is progressing and that she’s only angry she didn't get to tell the shooter “that he missed.”
AUA 2014: Studies shine light on new PCa tests, TRT safety
In our “Best of AUA” report, Urology Times’ editors and writers present the AUA annual meeting’s take-home messages in 15 therapeutic areas.
Early ADT for prostate cancer fails to improve survival
Androgen deprivation therapy provides no survival benefit in older men with localized prostate cancer at 15 years, newly published research shows.
Best of AUA 2014: Outcomes Analysis
Jesse D. Sammon, DO, presents the take home messages on outcomes analysis from the AUA annual meeting in Orlando, FL.
Best of AUA 2014: Bladder Cancer
Wassim Kassouf, MD, CM, presents the take home messages on bladder cancer from the AUA annual meeting in Orlando, FL.
Best of AUA 2014: Kidney Cancer
Monish Aron, MD, presents the take home messages on kidney cancer from the AUA annual meeting in Orlando, FL.
Studies reveal genes key to RCC development, growth
Two recently published Mayo Clinic studies provide genetic clues to clear cell renal cell carcinoma that may have important therapeutic implications, researchers say.
PCa screening: Shared decision making infrequent
Shared decision making occurs in only one-third of men who have made a decision about prostate cancer screening, according to findings from a new study that one leading prostate cancer expert said were not at all surprising.
Wide variation in VCUG reporting ‘embarrassing’
The significant variation in reporting of voiding cystourethrogram between free-standing pediatric and non-pediatric institutions unveiled in a recent study is “embarrassing,” according to one leading pediatric urologist.
FDA approves another testosterone replacement gel
FDA approves another testosterone replacement gel
The FDA has approved a new testosterone gel formulation, marking the agency’s second approval of a testosterone replacement therapy in the course of a week.

Poll